This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

EpiCast Report: Dry Eye Syndrome - Epidemiology Forecast To 2022





NEW YORK, April 11, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

EpiCast Report: Dry Eye Syndrome - Epidemiology Forecast to 2022

http://www.reportlinker.com/p01158446/EpiCast-Report-Dry-Eye-Syndrome---Epidemiology-Forecast-to-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

EpiCast Report: Dry Eye Syndrome - Epidemiology Forecast to 2022

Summary

Dry eye syndrome, also known as keratoconjunctivitis sicca (KCS), is a multi-factorial disease of the eye caused by dryness, decreased tear production, or increased tear film evaporation. It results in symptoms of discomfort such as visual disturbance and tear film instability (DEWS, 2007). Middle-aged and older adults are the most commonly affected group because of the high prevalence of contact lens usage, systemic drug effects, autoimmune diseases, and refractive surgeries in these group (Davis, 2003; Glasson et al., 2003; Schaumberg et al., 2002; Schaumberg et al., 2003; Toda et al., 2001).

Globally, dry eye has a prevalence of up to 33% (Clegg et al., 2006; Lemp et al., 2008; Schaumberg et al., 2002; Shimmura et al., 1999). The prevalence of dry eye is estimated to range from <0.1% to 33% across different countries and varies between 5% to >30% in various ages groups worldwide (Clegg et al., 2006; Lemp et al., 2008; Shimmura et al., 1999). Research also shows that dry eye syndrome is more prevalent in women than in men (Schaumberg et al., 2002).

Scope

- The Dry Eye Syndrome, EpiCast Report provides an overview of the risk factors and global trends of dry eye syndrome in the nine major markets (US, France, Germany, Italy, Spain, UK, Japan, China, and India). - It also includes a 10-year epidemiology forecast of the prevalent cases of dry eye syndrome, segmented by age (given in five-year increments beginning at age 45 years and ending at ages 85 years and older), sex, and severity in these markets.

Reasons to buy

- Develop business strategies by understanding the trends shaping and driving the global dry eye syndrome market.- Quantify patient populations in the global dry eye syndrome market to improve product design, pricing, and launch plans.- Organize sales and marketing efforts by identifying the age groups, sex, and severity levels that present the best opportunities for dry eye syndrome therapeutics in each of the markets covered.

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,269.64 +112.79 0.66%
S&P 500 2,011.14 +9.57 0.48%
NASDAQ 4,588.9290 +26.74 0.59%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs